AER 1588079 is a spontaneous case, received on 02/Jun/2015 from a physician via Therapeutic Goods 
Administration (TGA) (country: Australia, reference number: 353184) and concerns a 78 year old male patient who 
developed abnormal behavior and progressive multifocal leukoencephalopathy (PML) while treated with 
(Mabthera).
No medical history, concurrent conditions, concomitant medications or past drugs were reported.
On 28/Feb/2014, the patient started therapy with intravenous rituximab infusion solution (700 mg frequency not 
reported) for an unknown indication. On 10/Dec/2014, therapy with rituximab was stopped. On (b) (6)  he 
demonstrated behavioral change (event captured as abnormal behavior) due to which he was hospitalized. Nuclear
magnetic resonance imaging (MRI) of the brain was found to be abnormal and a brain biopsy demonstrated 
Print Time: 07-JUN-2016 03:01 PM If a field is blank, there is no data for that field Page 503 of 549
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
progressive multifocal leukoencephalopathy (PML).
At the time of this report, abnormal behavior was persisting and the outcome of progressive multifocal 
leukoencephalopathy was not reported.
The physician did not assess the seriousness of progressive multifocal leukoencephalopathy, but the company 
assessed the progressive multifocal leukoencephalopathy as medically significant.
The physician assessed the abnormal behavior and progressive multifocal leukoencephalopathy as possibly related
with rituximab.
No further information was provided.
This confirmed case of progressive multifocal leukoencephalopathy (PML) is being expedited per Genentech 
Enhanced Pharmacovigilance Plan for PML.